Meta-analyses on the impact of MDT care on hospitalisation and mortality in HF
| Meta-analysis | Number of studies | Number of patients | Outcome | ||
| All-cause mortality | All-cause hospitalisation | HF hospitalisation | |||
| McAlister et al 7* | 29 | 5039 | RR 0.75; 95% CI 0.59 to 0.96 | RR 0.81; 95% CI 0.71 to 0.92 | RR 0.74; 95% CI 0.63 to 0.87 |
| Holland et al 8 | 30 | 8243 | RR 0.79; 95% CI 0.69 to 0.92, P=0.002 | RR 0.87; 95% CI 0.79 to 0.95, P=0.002 | RR 0.70; 95% CI 0.61 to 0.8, P<0.001 |
| Takeda et al 9 | 25 | 5942 | OR 0.74; 95% CI 0.60 to 0.90, P=0.003 | OR 0.57; 95% CI 0.43 to 0.75, P<0.001 | |
*For interventions involving specialist MDT follow-up.
HF, heart failure; MDT, mltidisciplinary team; RR, relative risk.